Working... Menu

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03111992
Recruitment Status : Recruiting
First Posted : April 13, 2017
Last Update Posted : January 21, 2019
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : May 27, 2020
  Estimated Study Completion Date : May 27, 2020